Proprietary AI analyst is now available

Novogene Valuation Multiples

Discover revenue and EBITDA valuation multiples for Novogene and similar public comparables like New Horizon Health, Maravai LifeSciences, Diagnósticos da América, Castle Biosciences and more.

Novogene Overview

About Novogene

Novogene Co Ltd is engaged in providing multi-level scientific research and technical services and solutions for life science basic research, medical and clinical application research, and independent development and innovation of genetic testing medical equipment.


Founded

2011

HQ

China

Employees

N/A

Financials (LTM)

Revenue: $340M
EBITDA: $50M

EV

$589M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Novogene Financials

Novogene reported last 12-month revenue of $340M and EBITDA of $50M.

In the same LTM period, Novogene generated $145M in gross profit, $50M in EBITDA, and $27M in net income.

Revenue (LTM)


Novogene P&L

In the most recent fiscal year, Novogene reported revenue of $326M and EBITDA of $51M.

Novogene is profitable as of last fiscal year, with gross margin of 43%, EBITDA margin of 16%, and net margin of 8%.

See analyst estimates for Novogene
LTMLast FY202320242025202620272028
Revenue$340M$326M$296M$312M$326M
Gross Profit$145M$139M$126M$136M$139M
Gross Margin43%43%43%44%43%
EBITDA$50M$51M$53M$57M$51M
EBITDA Margin15%16%18%18%16%
EBIT Margin9%9%10%11%9%
Net Profit$27M$25M$26M$29M$25M
Net Margin8%8%9%9%8%

Financial data powered by Morningstar, Inc.

Novogene Stock Performance

Novogene has current market cap of $819M, and enterprise value of $589M.

Market Cap Evolution


Novogene's stock price is $1.97.

Novogene share price decreased by 5.7% in the last 30 days, and by 4.0% in the last year.

Novogene has an EPS (earnings per share) of $0.06.

See more trading valuation data for Novogene
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$589M$819M-3.5%-5.7%-3.4%-4.0%$0.06

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Novogene Valuation Multiples

Novogene trades at 1.7x EV/Revenue multiple, and 11.7x EV/EBITDA.

See NTM and 2027E valuation multiples for Novogene

EV / Revenue (LTM)


Novogene Financial Valuation Multiples

As of June 5, 2026, Novogene has market cap of $819M and EV of $589M.

Novogene has a P/E ratio of 29.9x.

LTMLast FY202320242025202620272028
EV/Revenue1.7x1.8x2.0x1.9x1.8x
EV/EBITDA11.7x11.6x11.0x10.3x11.6x
EV/EBIT18.5x20.7x20.0x17.7x20.8x
EV/Gross Profit4.0x4.2x4.7x4.3x4.2x
P/E29.9x33.2x31.1x28.2x33.2x
EV/FCF-35.4x18.3x19.6x35.4x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Novogene Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Novogene Margins & Growth Rates

Novogene grew revenue by 11% and EBITDA by 9% in the last fiscal year.

In the most recent fiscal year, Novogene reported gross margin of 43%, EBITDA margin of 16%, and net margin of 8%.

See estimated margins and future growth rates for Novogene

Novogene Margins

Last FY202420252026202720282029
Gross Margin43%44%43%43%
EBITDA Margin16%18%16%15%
EBIT Margin9%11%9%10%
Net Margin8%9%8%9%
FCF Margin5%10%5%-

Novogene Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth11%5%5%11%
Gross Profit Growth12%8%2%12%
EBITDA Growth9%6%(11%)9%
EBIT Growth28%13%(15%)28%
Net Profit Growth27%11%(15%)27%
FCF Growth-(7%)(44%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

Novogene Operational KPIs

Novogene's Rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Novogene's Rule of X is 42% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Novogene
LTMLast FY202320242025202620272028
Rule of 4026%26%---
Bessemer Rule of X43%42%---
S&M Expenses to Revenue20%20%5%5%7%
G&A Expenses to Revenue6%7%1%2%1%
R&D Expenses to Revenue7%7%6%6%7%
Opex to Revenue-34%33%33%34%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
New Horizon Health----
Maravai LifeSciences4.5x4.3x(27.0x)(178.2x)
Diagnósticos da América0.9x1.0x4.7x4.7x
Castle Biosciences1.2x1.2x10.0x16.8x
Vazyme Biotech3.6x3.4x34.3x21.4x
Jiangsu Bioperfectus8.8x-90.4x-
Assure Tech5.2x-19.0x-
Azenta1.2x1.2x11.0x11.7x

This data is available for Pro users. Sign up to see all Novogene competitors and their valuation data.

Start Free Trial

Novogene VC Funding History

Before going public, Novogene raised $75M in total equity funding, across 1 round.


Novogene Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Nov-16Series BChina Merchants Bank; CMB International Capital Corporation; SDIC Fund Management; Sigma Square Capital$75M-Novogene Co., Ltd. is a genomics company providing sequencing and bioinformatics services for research in precision medicine, biotechnology, and agricultural genomics. A table on dcfmodeling.com lists Novogene's 2016 revenue as USD 50 million, up 66.67% from USD 30 million in 2015, alongside 1,200 scientific publications that year. No details on the specific VC round in late 2016 involving China Merchants Bank, CMB International Capital Corporation, SDIC Fund Management, and Sigma Square Capital appear in the results, including no post-money valuation, round size confirmation beyond user query, or use of funds. Recent financials show Novogene's growth: 2024 annual revenue reached 2.11B CNY per stockanalysis.com, with trailing twelve months at 2.14B CNY as of Q1 2025, reflecting 5.45-5.66% year-over-year increases. Earlier dcfmodeling.com data notes 2021 revenue at approximately USD 137 million (up over 20% YoY), 2022 at USD 250 million with USD 35 million net profit. The company went public on the STAR Market (SHA:688315) and employs 2,202 people with revenue per employee at 974.05K CNY. No EBITDA figures, valuation multiples, or metrics tied to the 2016 round are available in sources. Revenue near 2016 remains the USD 50 million figure from the historical table, while later years indicate scaling operations, with 2022 geographical split showing 70% from China (1,200 RMB million), 17% North America, 12% Europe.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Novogene

When was Novogene founded?Novogene was founded in 2011.
Where is Novogene headquartered?Novogene is headquartered in China.
Is Novogene publicly listed?Yes, Novogene is a public company listed on Shanghai Stock Exchange.
What is the stock symbol of Novogene?Novogene trades under 688315 ticker.
When did Novogene go public?Novogene went public in 2021.
Who are competitors of Novogene?Novogene main competitors include New Horizon Health, Maravai LifeSciences, Diagnósticos da América, Castle Biosciences, Vazyme Biotech, Jiangsu Bioperfectus, Assure Tech, Azenta, Clinica Baviera, Fulgent Genetics.
What is the current market cap of Novogene?Novogene's current market cap is $819M.
What is the current revenue of Novogene?Novogene's last 12 months revenue is $340M.
What is the current revenue growth of Novogene?Novogene revenue growth (NTM/LTM) is 11%.
What is the current EV/Revenue multiple of Novogene?Current revenue multiple of Novogene is 1.7x.
What is the current EBITDA of Novogene?Novogene's last 12 months EBITDA is $50M.
What is Novogene's EBITDA margin?Novogene's last 12 months EBITDA margin is 15%.
What is the current EV/EBITDA multiple of Novogene?Current EBITDA multiple of Novogene is 11.7x.
How many companies Novogene has acquired to date?Novogene hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Novogene has invested to date?Novogene hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Novogene

Lists including Novogene

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial